Bio-Rad Laboratories (NYSE:BIO – Get Free Report) announced its quarterly earnings results on Thursday. The medical research company reported $2.33 EPS for the quarter, missing the consensus estimate of $2.87 by ($0.54), Briefing.com reports. Bio-Rad Laboratories had a negative net margin of 5.86% and a positive return on equity of 3.82%. The firm had revenue […]
Tobam acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 150 shares of the medical research company’s stock, valued at approximately $57,000. A number of other institutional investors also […]
Tobam purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 150 shares of the medical research company’s stock, valued at approximately $57,000. Other large investors have also modified their holdings of the company. Desjardins Global Asset Management Inc. bought a new stake in […]
Grantham Mayo Van Otterloo & Co. LLC decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 2.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,400 shares of the medical research company’s stock after selling 1,800 shares during the quarter. Grantham […]
American Century Companies Inc. grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 261.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,011 shares of the medical research company’s stock after purchasing an additional 34,008 shares during the quarter. […]